Development of Novel Physiological CMR Methods in Health and Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-80
SponsorSheffield Teaching Hospitals NHS Foundation Trust

About this trial

Physiological cardiovascular stress test plays a crucial role in the assessment of patients with suspected heart disease. There are several methods of cardiac physiological stress tests and each of them offer varied insight into cardiac physiological adaptation: passive leg raise, intra-venous fluid challenge, pharmacological stressors and physical exercise stress test. Echocardiography, which is the mainstay for the non-invasive rest/stress assessment of the left ventricular (LV) haemodynamics has several limitations. Novel methods of CMR imaging allow to map intra-cardiac flow in three-dimension using novel flow acquisitions. These novel flow acquisitions are called four-dimensional flow CMR, where the fourth dimension is time. Additionally, traditional cine CMR imaging for functional assessment can now be done without breath-holds using advanced acceleration methods, allowing them to be used during exercise. A comprehensive understanding of functional-flow coupling at rest, during increased pre-load (fluid challenge) to the heart or during exercise, is lacking in the literature. There is an important need to validate these novel CMR methods for developing mechanistic insight into physiological cardiac adaptation to increased pre-load or to exercise in health and how it alters in heart disease.

Eligibility criteria

Qualifiers

Healthy Volunteers age 20 to 80, recruited from Sheffield Teaching Hospitals staff members

Patients age 20 to 80 with suspected or known heart disease (group 1 to 5)

Capable of giving written informed consent

Disqualifiers

Inability to perform the study protocol secondary to severe heart failure requiring IV therapy

Patients recruited in the suspected CAD and acute myocardial infarction arms of the study and in need for detection of ischaemia should not have any past medical history of MI, ACS or cardiomyopathy

Patients with significant valvular heart disease will be excluded from any patient group

Patient with in atrial fibrillation will be excluded

Trial design

Treatments tested in this trial

  • intravenous fluid challenge

Treatment groups

135 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.